Soluble TREM-2 Antibodies

sTREM2 is the soluble form of the microglial receptor TREM2 and reflects microglial activation in neurodegenerative diseases¹. Cerbrospinal fluid (CSF) sTREM2 levels are increased in early symptomatic Alzheimer’s disease and show associations with tau pathology, neuronal injury, and neuroinflammation². Altered sTREM‑2 levels in CSF have also been reported in multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson’s disease, where they associate with inflammatory and neurodegenerative markers and, in some conditions, with measures of disease burden or progression^3,4,5. Dynamic changes in sTREM2 across disease stages suggest potential utility for tracking microglial responses and disease progression¹.

The ADx601 and ADx602 monoclonal antibodies targeting sTREM2 enable the development of immunoassays to further characterize microglial activation markers.